Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative breast cancer that is advanced (locally advanced or spread to other parts of the body)
- Your cancer has progressed despite at least one prior treatment (chemotherapy and/or hormone therapy, depending on cancer subtype)
- You have adequate organ function (normal blood counts, liver, and kidney function)
- You are 18 years or older and able to attend all study visits
- You do not have uncontrolled brain metastases, active heart disease, or uncontrolled autoimmune conditions
- If of child-bearing potential, you agree to use effective contraception and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding toripalimab (an immunotherapy drug) to chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if this combination works better than chemotherapy alone.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests whether combining the immunotherapy drug toripalimab with targeted radiation can help patients with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. It aims to find a new treatment option for these patients.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.